Microsoft word - document15

The Southwest Oncology Group Invites You to Attend the Spring 2007 Group Meeting At the Hyatt Regency Hotel in Chicago, Illinois To register for the meeting, review the schedule, plan your travel, and view details of the Group Meeting please use the link below. Also don’t miss our Plenary Session on Saturday, May 5, 2007, from 8:30 - 11:00 a.m. The highlight this year for the plenary session is Innovation for Increased
We all know, for example, the Europeans are currently conducting Phase III
trials more efficiently than Americans. The plenary presentations will focus on recent studies
completed through successful collaborations and/or innovative approaches. SWOG Group Chair
Laurence Baker, DO, will also give a presentation, “Strategic Response to Budget Cuts.” And as
always, there will be a few surprises!
Abstracts illustrating innovative approaches include:
S0124: Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and
Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
Presenter: Primo Lara, Jr, MD, UC Davis Cancer Center
C9710: Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or
Without Arsenic Trioxide (AS2O3) (NSC #706363) as Initial Consolidation Therapy
Followed by Intermittent Tretinoin Maintenance Therapy Versus Observation for Patients
with Untreated Acute Promyelocytic Leukemia
Presenter: Steven Coutre, MD, Stanford University
S0205: A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus
Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with
Advanced Pancreas Cancer
Presenter: Phillip Phillip, MD, PhD, Karmanos Cancer Center
S8897: Pharmacogenetics and Breast Cancer Treatment Outcomes: Results on
Oxidative Stress Related Genotypes (MPO, MnSOD) from a Southwest Oncology Group
Intergroup Trial
Presenter: Christine Ambrosone, PhD, Roswell Park Cancer Institute

Discussants include Fred Appelbaum, MD, Fred Hutchinson Cancer Center; Joe Nevins, PhD,
Duke University; Peter O’Dwyer, MD, University of Pennsylvania; Richard Schilsky, MD, CALBG,
University of Chicago; and other internationally renowned experts.
Our Translational Medicine Meeting, Friday, May 4, 4:30 - 6:00 p.m., will offer Translational
Medicine Strategies for Patient Enrichment.
Speakers include Joe Nevins, PhD, Director of the
IGSP Center for Genome Technology at Duke University; Peter O’Dwyer, MD, Experimental
Therapeutics Director at the University of Pennsylvania Cancer Center; and John Crowley, PhD,
SWOG Group Biostatistician and Director of the SWOG Statistical Center and Data Operations
For more information about the upcoming meeting, please see our Group Meeting News at
We look forward to your participation in the SPRING 2007 SWOG GROUP MEETING!


Microsoft word - food for thought revision 1 bloom 03-11-04.doc

Some Food for Thought About Effect Size Howard S. Bloom Mark W. Lipsey Vanderbilt University March 11, 2004 The following examples highlight some important facts of life about the metric of effect size. The definition of effect size that is used equals the difference in mean outcomes for two groups (usually a treatment group and a control group) divided by the standard d

Microsoft word - 125770_f_gi_11-08-23_endoxan 50mg dragee.doc

GEBRAUCHSINFORMATION: INFORMATION FÜR DEN ANWENDER ENDOXAN „Baxter“ 50 mg – Dragees Wirkstoff: Cyclophosphamidmonohydrat Lesen Sie die gesamte Packungsbeilage sorgfältig durch, bevor Sie mit der Einnahme dieses Arzneimittels beginnen. - Heben Sie die Packungsbeilage auf. Vielleicht möchten Sie diese später nochmals lesen. Wenn Sie weitere Fragen haben, wenden Sie s

© 2008-2018 Medical News